M&A / Deals Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments Pharmaceutical Business ReviewThese conditions often result in organ failure due to myofibroblast activation, scarring, and tissue inflammation.Immunology & InflammationRead full story pharminent August 7, 2026 (Last updated: August 8, 2026) Pharmaceutical Business Review These conditions often result in organ failure due to myofibroblast activation, scarring, and tissue inflammation. Immunology & Inflammation Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Replimune rebounds to win FDA approval of melanoma drugNext: Intellia finds genetic suspect for liver safety signals with ATTR gene therapy Related Stories M&A / Deals Supernus and Indivior merge to create scaled, CNS-focused entity pharminent August 4, 2026 M&A / Deals Pathos AI signs two cancer deals with Alphamab and AZ pharminent August 4, 2026 M&A / Deals Supernus and Indivior merge to create CNS mega-company with 11 approved drugs pharminent August 3, 2026
